

Michael Guger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1542444/publications.pdf>

Version: 2024-02-01

17
papers

336
citations

933447

10
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

382
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. <i>European Journal of Neurology</i> , 2022, 29, 1538-1544.	3.3	12
2	Favorable benefit-risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria. <i>ENeurologicalSci</i> , 2022, 27, 100396.	1.3	0
3	Long-term outcome after COVID-19 infection in multiple sclerosis: A nationwide multicenter matched-control study. <i>European Journal of Neurology</i> , 2022, 29, 3050-3060.	3.3	9
4	Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104009.	2.0	3
5	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110396.	3.5	86
6	Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. <i>Journal of Neurology</i> , 2021, 268, 4303-4310.	3.6	8
7	Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study. <i>Frontiers in Immunology</i> , 2021, 12, 641106.	4.8	2
8	COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. <i>PLoS ONE</i> , 2021, 16, e0255316.	2.5	27
9	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2209-2218.	3.0	25
10	Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry. <i>Frontiers in Neurology</i> , 2020, 11, 676.	2.4	5
11	Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method. <i>Journal of Neurology</i> , 2020, 267, 2090-2100.	3.6	7
12	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
13	Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry. <i>Journal of Neurology</i> , 2019, 266, 2672-2677.	3.6	14
14	Real-life use of oral disease-modifying treatments in Austria. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 32-39.	2.1	15
15	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	2.3	22
16	Caregiving and Caregiver Burden in Dementia Home Care: Results from the Prospective Dementia Registry (PRODEM) of the Austrian Alzheimer Society. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 103-114.	2.6	41
17	Real-life clinical use of natalizumab and fingolimod in Austria. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 181-187.	2.1	28